FDetails
Product Testing Program
Commencing February 1, 2014 the cost of testing new and existing products, in addition to, any other initiative, will be the sole responsibility of the vendor. Silliker Canada has provided Loblaw control brand vendors with a discounted 4 Tier Flat Rate pricing platform (Appendix 1) incorporating basic testing requirements, additional claim testing and sensory description or “fingerprinting” for each new product.
Note:
Products that fail product testing and/or are subject to a recall and/or CFIA investigation may be subject to retesting at the vendors expense.
Non-Food products will continue to be subject to the Product Testing cost for “New” products (based on the new 4 Tier Flat Rate pricing platform) and are not subject to annual re-testing at this time.
Nutritional Analysis Verification
Silliker Canada will monitor the verification of nutritional analysis every 2 years and notify Loblaw and the vendors as to when samples need to be resubmitted for nutritional analysis. Silliker Canada has provided a customized Loblaw Nutritional Testing package at a reduced rate. (Appendix 1)
Invoicing
Invoicing will be managed directly between Silliker Canada and our vendors and consequently it is mandatory that the Silliker Client Information Sheet (CIS) and Vendor Product List Form found on the following link are completed and signed no later than February 21, 2014.
http://info.silliker.com/SillikerLoblaws2011/
If you already completed this form in 2011 please review your form and resubmit it even if no changes are required.
As part of the Loblaw Quality Assurance Program it is mandatory that Loblaw has access to all Product Testing information related to Loblaw control brand products generated by Silliker by allowing Silliker to upload the testing information into the Silliker Total Quality and Information Management (TQIM) system. This authorization has been incorporated into the CIS document.
Recall Cost Recovery Fee
Costs associated with the administering of product recalls (critical or non-critical) and product withdrawals will be in accordance with the schedule in Appendix 2.